生物技术提高海洋生境药用放线菌代谢产物的研究  

The Research on Biotechnology Improving the Metabolic Product of Marine Habitat Medicinal Actinomycetes

作　　者：马湘君[1,2] 史振平 张久明[1] 田黎[1,2] Xiangjun Ma;Zhenping Shi;Jiuming Zhang;Li Tian(Qingdao University of Science and Technology, Qingdao;First Institute of Oceanography, State Oceanic Administration, Qingdao)

机构地区：[1]青岛科技大学,青岛 [2]国家海洋局第一海洋研究所,青岛

出　　处：《海洋科学前沿》2014年第1期27-34,共8页Advances in Marine Sciences

基　　金：“十二五”国家科技支撑计划(2011BAE06B04);国家高技术“863”研究发展计划(2011AA10A202-2)。

摘　　要：海洋生境放线菌可产生较特异的药用化合物,但通常量很少很难满足后续的研究要求,原生质体融合技术是改良放线菌菌株最常用的育种方法之一,本文结合相关研究进展,分析了影响放线菌原生质体制备和融合的因素,介绍了放线菌融合子的筛选方法及应用,并对如何利用融合及基因技术等方法提高放线菌药用抗生素的产量进行了评述。Marine habitat actinomycetes can produce peculiar medicinal compounds, but the amount is not enough to meet the requirements of further study. Protoplast fusion technology is one of the most common methods of breeding to improve strains of actinomycetes. This article combined related progress, analyzed the factors that influenced the actinomycetes protoplast fusion, introduced the screening methods of actinomycetes fusants, and commented on the means as to how to use genetic engineering to increase the titer of actinomycetes medicinal antibiotics.

关 键 词：放线菌 药用化合物 原生质融合 基因技术 

分 类 号：G6[文化科学—教育学]